Photocure ASA ( (PHCUF) ) has released its Q1 earnings. Here is a breakdown of the information Photocure ASA presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Photocure ASA is a company specializing in the development and commercialization of solutions for the detection and treatment of bladder cancer, with its flagship product Hexvix/Cysview being used for non-muscle invasive bladder cancer (NMIBC) detection.
In the first quarter of 2025, Photocure reported a 7% increase in revenue from its Hexvix/Cysview product, reaching NOK 125.3 million, driven by growth in both Europe and North America. The company also expanded its blue light cystoscopy technology with new installations and upgrades in the U.S. and Europe.
Key financial highlights include a decrease in commercial EBITDA to NOK 6.8 million from NOK 11.7 million the previous year, and a net loss of NOK 2.4 million, despite increased revenues. The company completed a share buy-back program, repurchasing 500,000 shares, and announced the availability of an interim flexible BLC solution in several countries.
Looking forward, Photocure expects product revenue growth between 7% and 11% for 2025, with an improvement in EBITDA. The company plans to continue expanding its market presence in North America and Europe, focusing on increasing the adoption of its blue light cystoscopy technology.